Xiaoyin Ke1, Yi Ding2, Ke Xu3, Hongbo He2, Minling Zhang2, Daping Wang2, Xuefeng Deng4, Xifan Zhang4, Chao Zhou2, Yuping Liu2, Yuping Ning2, Ni Fan5. 1. Guangzhou Brain Hospital, The Affiliated Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong 510370, China; Shenzhen Mental Health Center, 1080 Cuizhu Road, Luohu District, Shenzhen, Guangdong 518020, China. 2. Guangzhou Brain Hospital, The Affiliated Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong 510370, China. 3. Department of Psychiatry, Yale School of Medicine, 300 George street, New Haven, CT 06510, USA. 4. Guangzhou Baiyun Voluntary Drug Rehabilitation Hospital, 586 North of Baiyun Road, Baiyun District, Guangzhou, Guangdong 510440, China. 5. Guangzhou Brain Hospital, The Affiliated Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong 510370, China. Electronic address: fanni2005@126.com.
Abstract
AIMS: This study investigated the serum levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in a group of chronic ketamine abusers in comparison to healthy controls. The correlations between the serum BDNF, NGF level with the subjects' demographic, pattern of ketamine use were also examined. METHODS: 93 subjects who met the criteria of ketamine dependence and 39 healthy subjects were recruited. Serum BDNF and NGF levels were assayed by enzyme-linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). RESULTS: Both serum levels of BDNF and NGF were significant lower in the ketamine users compared to the healthy control subjects (9.50±6.68 versus 14.37±6.07 ng/ml, p=0.019 for BDNF; 1.93±0.80 versus 2.60±1.07 ng/ml, p=0.011 for NGF). BDNF level was negatively associated with current frequency of ketamine use (r=-0.209, p=0.045). CONCLUSIONS: Both BDNF and NGF serum concentrations were significantly lower among chronic ketamine users than among health controls.
AIMS: This study investigated the serum levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in a group of chronic ketamine abusers in comparison to healthy controls. The correlations between the serum BDNF, NGF level with the subjects' demographic, pattern of ketamine use were also examined. METHODS: 93 subjects who met the criteria of ketamine dependence and 39 healthy subjects were recruited. Serum BDNF and NGF levels were assayed by enzyme-linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). RESULTS: Both serum levels of BDNF and NGF were significant lower in the ketamine users compared to the healthy control subjects (9.50±6.68 versus 14.37±6.07 ng/ml, p=0.019 for BDNF; 1.93±0.80 versus 2.60±1.07 ng/ml, p=0.011 for NGF). BDNF level was negatively associated with current frequency of ketamine use (r=-0.209, p=0.045). CONCLUSIONS: Both BDNF and NGF serum concentrations were significantly lower among chronic ketamine users than among health controls.
Authors: Celia J A Morgan; Susan L Rossell; Fiona Pepper; James Smart; James Blackburn; Brigitta Brandner; H Valerie Curran Journal: Biol Psychiatry Date: 2005-09-02 Impact factor: 13.382
Authors: Jason Ng; Leanna M W Lui; Joshua D Rosenblat; Kayla M Teopiz; Orly Lipsitz; Danielle S Cha; Jiaqi Xiong; Flora Nasri; Yena Lee; Kevin Kratiuk; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Roger Ho; Bing Cao; Roger S McIntyre Journal: Psychopharmacology (Berl) Date: 2021-01-23 Impact factor: 4.530